Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oligomannate

- PMLiVE

UCL study finds certain ethnicities experience greater effect of dementia risk factors

Researchers analysed health data from nearly one million adults in England

- PMLiVE

Alzheimer’s Research UK awards Cardiff University researchers £387,000

The researchers will investigate how genes accelerate the development of Alzheimer’s disease

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

MIT study finds drug candidate reduces inflammation in Alzheimer’s models

The candidate significantly reduced inflammation and improved cognitive functions

- PMLiVE

Alzheimer’s Research UK calls on party leaders to tackle dementia pressures

One in three people living with dementia in England never receive a formal diagnosis

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Alzheimer’s Research UK awards £370,000 to University of Exeter researchers

The grants are part of a wider £3m funding announcement that aims to accelerate effective treatments for dementia

- PMLiVE

Quest Diagnostics launches Alzheimer’s blood test for US consumers

Alzheimer's disease is expected to affect around 14 million people in the US by 2060

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation

Leqembi was granted traditional approval in the US earlier this month as a bi-weekly intravenous infusion

- PMLiVE

Eli Lilly’s Alzheimer’s drug confirmed to significantly slow disease progression

The full phase 3 results presented at AAIC reinforce the cognitive benefits of donanemab

- PMLiVE

Alnylam presents promising results for RNAi therapeutic in Alzheimer’s disease at AAIC

ALN-APP is the first investigational RNAi therapeutic to show gene silencing in the human brain

- PMLiVE

Acumen shares positive results for investigational Alzheimer’s disease therapy at AAIC

The results will be discussed with regulators to assess next steps for clinical development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links